Wednesday, March 22, 2023
THE SENIOR HEALTH LETTER
No Result
View All Result
  • Home
  • Home Care
  • Elder Care
  • Wellness
  • Dementia
  • Caregivers
  • Alzheimer’s
  • Assisted living
  • Mindfulness
  • Seniors advocate
The Senior Health Letter
No Result
View All Result
Home Alzheimer's

Cognito Therapeutics touts positive Phase 2 results for device-delivered Alzheimer’s treatment

Delmar by Delmar
March 12, 2021
in Alzheimer's
0
Cognito Therapeutics touts positive Phase 2 results for device-delivered Alzheimer’s treatment
0
SHARES
5
VIEWS
Share on FacebookShare on Twitter


Yesterday Cognito Therapeutics, a startup utilizing visible and auditory stimulation to deal with neurodegenerative issues, introduced Part 2 trial outcomes suggesting its gamma frequency neuromodulation remedy slowed declines in reminiscence and cognition amongst mild-to-moderate Alzheimer’s illness sufferers.

The OVERTURE study, a multi-center, randomized managed trial, enrolled 76 such sufferers aged 50 years or older starting in 2018. These contributors had been randomized to obtain both Cognito’s audio-visual stimulation remedy or a sham stimulation for one hour every day of their house.

All through the six-month remedy interval, Cognito mentioned the remedy group (n = 33) in comparison with the placebo group (n =20) demonstrated a major 84% slowdown in practical decline and a major 83% decline in cognitive impairment, as measured utilizing standardized scales each 4 weeks. As well as, there was a major 61% discount in entire mind atrophy and volumetric loss amongst 30 remedy group contributors compared to 19 placebo group contributors, in keeping with the corporate.

“Our strategy has translated into medical proof of idea by efficiently attaining statistically important leads to [Alzheimer’s disease], with a possible for illness modification as a result of important discount of cerebral atrophy and volumetric loss,” Dr. Tom Megerian, chief medical officer of Cognito Therapeutics, mentioned in a press release. “Along with bettering practical outcomes, reminiscence and cognition, the 61% discount in lack of entire mind quantity in our Part 2 research addresses key points of [Alzheimer’s disease] etiology and illness development. If these outcomes are replicated in our bigger, pivotal trial, this can signify an enormous medical breakthrough in Alzheimer’s analysis.”

Exterior of those top-line outcomes, Cognito is reporting the research outcomes this week on the 2021 AD/PD, a convention on Alzheimer’s and Parkinson’s illnesses and associated neurological issues, and will likely be holding a digital panel with executives and researchers on Friday concerning these and prior analysis information on the remedy.

WHAT’S THE IMPACT

Cognito’s lead product is a tool delivering flickering lights and different stimuli to induce gamma oscillations, a sample of mind waves that analysis suggests is expounded to cognition. The startup licensed the know-how from MIT researchers and cofounders Li-Huei Tsai and Ed Boyden, and in January of this yr acquired a Breakthrough Gadget Designation from the FDA.

With these constructive outcomes, Cognito mentioned it’ll now transfer ahead with a large-scale pivotal medical trial of the remedy and – ought to that effort pan out as nicely – the FDA approval course of.

“With our current FDA Breakthrough Gadget Designation, we stay up for expediting the medical improvement of what has the promise to be the primary disease-modifying digital therapeutic in Alzheimer’s illness,” CEO Brent Vaughan mentioned in a press release.

THE LARGER TREND

Cognito – which manufacturers itself as a digital therapeutic firm – is joined within the Alzheimer’s area by Neuroglee Therapeutics, a Singapore-based startup that raised $2.3 million in pre-seed funding in December to deal with neurodegenerative illnesses with synthetic intelligence, machine studying and digital biomarkers. Wanting additional again, Cognito’s Breakthrough Gadget Designation was preceded by neurodegenerative digital therapeutics firm Dthera Sciences, which gained the designation in 2018.

Alzheimer’s and different neurodegenerative illnesses have additionally been a spotlight for the broader digital well being area. Sensors and software program from wearables, apps and different instruments have been used to identify early circumstances, main Biogen and Apple to not too long ago announce a brand new observational research on the topic.



Source link

Tags: AlzheimersCognitodevicedeliveredPhasepositiveResultsTherapeuticstoutstreatment
Advertisement Banner
Previous Post

WATCH NOW: Local FCCLA students advocate for the district’s COVID plan – Scottsbluff Star Herald

Next Post

States should fund senior living, relax visitation, association leaders tell governors – News

Delmar

Delmar

Next Post
States should fund senior living, relax visitation, association leaders tell governors – News

States should fund senior living, relax visitation, association leaders tell governors - News

Discussion about this post

Recommended

Construction contract for Old Crow Wellness Centre awarded to Ketza Construction Ltd. – Yukon News

Construction contract for Old Crow Wellness Centre awarded to Ketza Construction Ltd. – Yukon News

2 years ago
A Former Huntington’s Caregiver Shares Her Best Caregiving Tips

A Former Huntington’s Caregiver Shares Her Best Caregiving Tips

2 years ago

Don't Miss

(2021-2026) Nursing Home Beds Market Size, Demand Status | Global Industry Segment Analysis, Growing Status of Key Players

Advice You Need To Know About Personal Development

May 12, 2021
Asceneuron Receives USD 2.2 Million Award from the Alzheimer’s Drug Discovery Foundation

Advocate Aurora Enterprises acquires national leader in home care and wellness offerings Senior Helpers

April 1, 2021
‘I’m in jail’: BPS mothers and caregivers voice concerns with district reopening plans

‘I’m in jail’: BPS mothers and caregivers voice concerns with district reopening plans

April 1, 2021
As Loved Ones Reunite After A Year, Dementia Experts Offer These Tips

As Loved Ones Reunite After A Year, Dementia Experts Offer These Tips

April 1, 2021

Categories

  • Alzheimer's
  • Assisted living
  • Caregivers
  • Dementia
  • Elder Care
  • Home Care
  • Mindfulness
  • Seniors advocate
  • Uncategorized
  • Wellness

Follow us

Recent News

(2021-2026) Nursing Home Beds Market Size, Demand Status | Global Industry Segment Analysis, Growing Status of Key Players

Advice You Need To Know About Personal Development

May 12, 2021
Asceneuron Receives USD 2.2 Million Award from the Alzheimer’s Drug Discovery Foundation

Advocate Aurora Enterprises acquires national leader in home care and wellness offerings Senior Helpers

April 1, 2021
March 2021
S M T W T F S
 123456
78910111213
14151617181920
21222324252627
28293031  
    Apr »
  • About Us
  • Contact Us
  • Privacy & Policy

© 2021 The Senior health Letter

No Result
View All Result
  • Home
  • Home Care
  • Elder Care
  • Wellness
  • Dementia
  • Caregivers
  • Alzheimer’s
  • Assisted living
  • Mindfulness
  • Seniors advocate

© 2021 The Senior health Letter